United Therapeutics Corporation (UTHR) - Latest Market Data

Track the most recent price, market cap, volume, and performance data for United Therapeutics Corporation (UTHR).

Download S&P Stocks on Google Play Download S&P Stocks on the App Store

Equity Overview

Price & Market Data

Price: $434.1

Daily Change: +$19.33 / 4.45%

Daily Range: $413.0 - $438.3

Market Cap: $19,630,911,488

Daily Volume: 1,141,092

Performance Metrics

1 Week: 9.07%

1 Month: 39.02%

3 Months: 49.71%

6 Months: 35.70%

1 Year: 23.55%

YTD: 23.02%

Company Details

Employees: 1305

Sector: Health technology

Industry: Pharmaceuticals: major

Country:

Details

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Selected stocks

Marcus & Millichap, Inc. (MMI)

Medical Properties Trust, Inc. (MPW)

Millrose Properties Inc Class A (MRP)